A delayed clinical trial actually boosted Bristol Myers Squibb’s stock.
Here’s why.
-
Bristol Myers’ stock rallied Wednesday as investors maintained high hopes
for Cobenfy as an Alzheimer’s treatment, even though the outcome of a
late-stage ...
35 minutes ago





"There are three kinds of lies: lies, damned lies, and statistics." - Benjamin Disraeli
ReplyDelete